Incannex Healthcare IXHL 深 滬
等待開盤 05-19 09:30:00 美东时间
3.79
-0.170
-4.29%
華盛通- 最 高4.00
- 今 開3.97
- 成交量 29.18万股
- 最 低 3.65
- 昨 收 3.96
- 總市值 5283.87万
- 52周最高 49.80
- 市盈率 靜 --
- 換手率 2.09%
- 52周最低 2.49
- 委 比 -42.72%
- 總股本 1394.16万
- 歷史最高 10800.00
- 量 比 0.93
- 振 幅 8.84%
- 歷史最低 2.40
- 每 手 1
- 風險率 6.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Incannex Healthcare Q3 EPS $(0.35) Beats $(0.79) Estimate
Incannex Healthcare (NASDAQ:IXHL) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.79) by 55.7 percent. This is a 94.35 percent increase over losses of $(6.19) per share
05-16 07:07
Incannex Q3 FY26 operating loss narrows 19% to USD 4.05 million
Incannex Q3 FY26 operating loss narrows 19% to USD 4.05 million Incannex Healthcare posted a comprehensive loss of USD 4.35 million for quarter ended March 31, 2026, widening 7% from USD 4.06 million a year earlier. Operating loss narrowed 19% to USD 4.05 million as research and development costs fe
05-15 21:30
Incannex Wins MedTech Award for IHL-42X Sleep Therapy
Incannex Healthcare Limited Sponsored ADR ( ($IXHL) ) has shared an announcemen...
05-12 20:42
Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development
Incannex Healthcare Inc. has won the "Best New Technology Solution for Drug Development" award at the 10th annual MedTech Breakthrough Awards for its lead drug candidate, IHL-42X, an oral therapy for obstructive sleep apnea (OSA). IHL-42X combines dronabinol and acetazolamide to target key drivers of OSA, showing significant reductions in AHI and improvements in sleep quality in Phase 2 trials. The award highlights Incannex's innovative approach ...
05-12 12:00
Incannex Highlights Psilocybin Anxiety Program Amid U.S. Policy Shift
Incannex Healthcare Limited Sponsored ADR ( ($IXHL) ) has provided an announcem...
04-22 20:34
Incannex Healthcare Says It Believes PSX-001 Development Program Aligns With Goals Outlined In Executive Order, Accelerating Medical Treatments For Serious Mental Illness
Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today supports the White House Executive Order signed by President Donald J. Trump on April
04-22 20:08
Incannex Reactivates Share Buyback, Signaling Valuation Confidence
The latest update is out from Incannex Healthcare Limited Sponsored ADR ( ($IXH...
03-27 21:17
BRIEF-Incannex Reactivates Share Repurchase Program, Underscoring Confidence In Valuation And Strategic Position
BRIEF-Incannex Reactivates Share Repurchase Program, Underscoring Confidence In Valuation And Strategic Position Incannex Healthcare Inc IXHL.O : INCANNEX REACTIVATES SHARE REPURCHASE PROGRAM, UNDERSCORING CONFIDENCE IN VALUATION AND STRATEGIC POSITION Source text: ID:nGNX8G1VpZ Further company cove
03-27 20:05
Incannex Healthcare Reactivates Previously Approved Buyback Plan
Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has reactivated its previously approved share repurchase program,
03-27 20:03
Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research
Incannex Healthcare joins the AASM Foundation's Corporate Recognition Program and sponsors a research grant for junior investigators focused on sleep apnea. The company advances IHL-42X, an oral treatment for obstructive sleep apnea, with recent milestones including positive Phase 2 results, FDA Fast Track designation, and the onset of the DReAMzz Phase 2 study. The partnership supports innovation and the next generation of sleep medicine researc...
03-25 12:00
